双时间点68Ga-DOTA-Exendin 4 PET/CT检测胰岛素瘤
本研究在10例临床和生化疑似胰岛素瘤的患者中,于注射68Ga-DOTA-Exendin 4后1小时(PET1)和2小时(PET2)行PET/CT,由2名独立读者视觉评估示踪剂摄取。8/10例患者见局灶性摄取增高,其中7例手术病理证实胰岛素瘤;PET2肿瘤SUVmax较PET1显著升高,但TBR无显著改善。作者认为单次1小时68Ga-DOTA-Exendin 4 PET/CT扫描足以满足患者诊疗需要。
要点
- 8/10例疑似胰岛素瘤患者双读者一致见局灶性68Ga-DOTA-Exendin 4摄取增高。
- 7例局灶性摄取患者行手术切除,病理均证实胰岛素瘤(7/8)。
- PET2肿瘤SUVmax较PET1显著升高,但TBR无显著改善。
核心结论
- 68Ga-DOTA-Exendin 4局灶性摄取可靠提示胰岛素瘤,所有接受后续手术的患者均经组织病理学证实。
- PET2的诊断价值未优于PET1,提示单次1小时68Ga-DOTA-Exendin 4 PET/CT扫描是充分且便捷的诊疗方法。
研究设计与样本
- 回顾性分析纳入10例临床和生化疑似胰岛素瘤的患者。
- 注射68Ga-DOTA-Exendin 4后1小时(PET1)和2小时(PET2)行PET/CT,由2名独立读者视觉评估示踪剂摄取,并评估局灶性病变的SUVmax和肿瘤-本底比(TBR)。
- 影像结果与接受切除患者的手术病理结果进行比较。
主要发现
- 8/10例患者双读者一致观察到局灶性68Ga-DOTA-Exendin 4摄取增高。
- 7例局灶性摄取患者行手术肿瘤剜除,组织病理学证实胰岛素瘤(7/8)。
- 10例中2例无局灶性摄取者被认为患弥漫型先天性高胰岛素血症,接受药物治疗。
- PET2肿瘤SUVmax较PET1显著升高(PET1:SUVmax 20.2 ± 8.2 g/mL vs PET2:SUVmax 24.7 ± 7.9 g/mL,P = 0.0018)。
- TBR在PET1与PET2间无显著改善(PET1:TBR 4.9 ± 1.7 vs PET2:TBR 4.3 ± 1.2,P = 0.2892)。
关键数值与推荐
- 局灶性68Ga-DOTA-Exendin 4摄取增高:8/10例患者双读者一致判定。
- 手术病理证实胰岛素瘤:7/8例局灶性摄取患者。
- PET1肿瘤SUVmax 20.2 ± 8.2 g/mL,PET2肿瘤SUVmax 24.7 ± 7.9 g/mL,P = 0.0018。
- PET1 TBR 4.9 ± 1.7,PET2 TBR 4.3 ± 1.2,P = 0.2892。
临床怎么用
- 作者认为单次1小时68Ga-DOTA-Exendin 4 PET/CT扫描是充分且便捷的诊疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Insulinomas are predominantly benign neuroendocrine tumors originating from beta cells within the islets of Langerhans of the endocrine pancreas. Because surgical resection represents the only curative therapy option, exact tumor localization and discrimination of insulinomas from focal or diffuse manifestations of congenital hyperinsulinism are crucial for optimal treatment strategies. We investigated the diagnostic value of glucagon-like peptide 1 receptor PET/CT using Ga-DOTA-exendin 4 for detecting insulinomas and compared the diagnostic value of PET scans performed at 2 time points. METHODS: In 10 patients with clinically and biochemically suspected insulinoma, PET/CT was performed at 1 hour (PET1) and 2 hours (PET2) after injection of Ga-DOTA-exendin 4. In this retrospective analysis, tracer uptake was visually assessed in both scans by 2 independent readers. SUVmax and tumor-to-background ratio (TBR) of focal lesions were assessed. Imaging results were compared with histopathologic findings, if patients underwent resection. RESULTS: Increased focal Ga-DOTA-exendin 4 uptake was observed in 8 of 10 patients concordantly by both readers. Seven patients with focal uptake underwent surgery with tumor enucleation and histopathologic proof of insulinoma (7/8). Two of 10 patients without focal uptake were considered to suffer from diffuse form of congenital hyperinsulinism and consequently received medical treatment. A significant increase of tumoral SUVmax on PET2 (PET1: SUVmax 20.2 ± 8.2 g/mL; PET2: SUVmax 24.7 ± 7.9 g/mL; P = 0.0018) did not result in a significant improvement in TBR (PET1: TBR 4.9 ± 1.7; PET2: TBR 4.3 ± 1.2; P = 0.2892). CONCLUSIONS: Focal uptake of Ga-DOTA-exendin 4 reliably indicated insulinomas as histopathologically confirmed in all patients undergoing consecutive surgery. The diagnostic value of PET2 was not found to be superior to PET1, indicating that a single 1-hour Ga-DOTA-exendin 4 PET/CT scan is a sufficient and convenient approach for patient care.
引用
- Michalski K, Laubner K, Stoykow C, et al. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT. Clin Nucl Med. 2020. PMID: 32453080. doi:10.1097/RLU.0000000000003093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。